Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
retlirafusp alfa + indole-3-carbinol + black garlic fermentation extract + Lactobacillus rhamnosus + paclitaxel + cisplatin + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This experimental combination regimen is a biomarker-guided precision treatment strategy being evaluated for the first-line treatment of advanced metastatic esophageal squamous cell carcinoma (ESCC). The regimen consists of a backbone of TP chemotherapy (paclitaxel and cisplatin) and a PD-1 inhibitor, supplemented by additional agents based on patient biomarker profiles: retlirafusp alfa (a bifunctional PD-L1/TGF-βRII fusion protein) for TGF-β positive patients; indole-3-carbinol and black garlic fermentation extract for metabolite-guided intervention; or Lactobacillus rhamnosus for microbiome-guided intervention. This multi-modal approach aims to enhance anti-tumor immunity by simultaneously targeting immune checkpoints, the TGF-β signaling pathway, and the gut-microbiome-tumor axis.
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)TUBB (Tubulin (alpha and beta subunits))AHR (Aryl hydrocarbon receptor)TGFBR2 (TGF-β receptor type 2)
Beyond the preview
Go deeper on retlirafusp alfa + indole-3-carbinol + black garlic fermentation extract + Lactobacillus rhamnosus + paclitaxel + cisplatin + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on retlirafusp alfa + indole-3-carbinol + black garlic fermentation extract + Lactobacillus rhamnosus + paclitaxel + cisplatin + PD-1 inhibitor.